UNIVERSAL TECHNICAL INSTITUT (UTI) Fundamental Analysis & Valuation
NYSE:UTI • US9139151040
Current stock price
35.49 USD
-0.84 (-2.31%)
At close:
35.49 USD
0 (0%)
After Hours:
This UTI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. UTI Profitability Analysis
1.1 Basic Checks
- In the past year UTI was profitable.
- UTI had a positive operating cash flow in the past year.
- UTI had positive earnings in each of the past 5 years.
- Each year in the past 5 years UTI had a positive operating cash flow.
1.2 Ratios
- With a decent Return On Assets value of 6.44%, UTI is doing good in the industry, outperforming 73.97% of the companies in the same industry.
- UTI has a Return On Equity of 15.98%. This is in the better half of the industry: UTI outperforms 75.34% of its industry peers.
- The Return On Invested Capital of UTI (8.69%) is better than 75.34% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for UTI is significantly below the industry average of 15.40%.
- The 3 year average ROIC (7.27%) for UTI is below the current ROIC(8.69%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.44% | ||
| ROE | 15.98% | ||
| ROIC | 8.69% |
ROA(3y)4.45%
ROA(5y)3.5%
ROE(3y)11.95%
ROE(5y)9.34%
ROIC(3y)7.27%
ROIC(5y)5.89%
1.3 Margins
- The Profit Margin of UTI (6.28%) is better than 65.75% of its industry peers.
- UTI's Profit Margin has improved in the last couple of years.
- UTI's Operating Margin of 8.38% is fine compared to the rest of the industry. UTI outperforms 67.12% of its industry peers.
- In the last couple of years the Operating Margin of UTI has grown nicely.
- UTI has a Gross Margin (49.62%) which is comparable to the rest of the industry.
- UTI's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.38% | ||
| PM (TTM) | 6.28% | ||
| GM | 49.62% |
OM growth 3Y17.03%
OM growth 5YN/A
PM growth 3Y35.13%
PM growth 5Y53.06%
GM growth 3Y-13.36%
GM growth 5Y-8.21%
2. UTI Health Analysis
2.1 Basic Checks
- UTI has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- The number of shares outstanding for UTI has been increased compared to 1 year ago.
- UTI has more shares outstanding than it did 5 years ago.
- The debt/assets ratio for UTI has been reduced compared to a year ago.
2.2 Solvency
- An Altman-Z score of 3.95 indicates that UTI is not in any danger for bankruptcy at the moment.
- UTI's Altman-Z score of 3.95 is fine compared to the rest of the industry. UTI outperforms 78.08% of its industry peers.
- The Debt to FCF ratio of UTI is 6.28, which is on the high side as it means it would take UTI, 6.28 years of fcf income to pay off all of its debts.
- Looking at the Debt to FCF ratio, with a value of 6.28, UTI is in the better half of the industry, outperforming 69.86% of the companies in the same industry.
- UTI has a Debt/Equity ratio of 0.29. This is a healthy value indicating a solid balance between debt and equity.
- UTI has a Debt to Equity ratio of 0.29. This is comparable to the rest of the industry: UTI outperforms 57.53% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | 6.28 | ||
| Altman-Z | 3.95 |
ROIC/WACC1
WACC8.73%
2.3 Liquidity
- A Current Ratio of 1.14 indicates that UTI should not have too much problems paying its short term obligations.
- The Current ratio of UTI (1.14) is comparable to the rest of the industry.
- UTI has a Quick Ratio of 1.14. This is a normal value and indicates that UTI is financially healthy and should not expect problems in meeting its short term obligations.
- With a Quick ratio value of 1.14, UTI perfoms like the industry average, outperforming 46.58% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.14 | ||
| Quick Ratio | 1.14 |
3. UTI Growth Analysis
3.1 Past
- The earnings per share for UTI have decreased by 0.00% in the last year.
- The Earnings Per Share has been growing by 65.96% on average over the past years. This is a very strong growth
- Looking at the last year, UTI shows a quite strong growth in Revenue. The Revenue has grown by 12.59% in the last year.
- Measured over the past years, UTI shows a very strong growth in Revenue. The Revenue has been growing by 22.67% on average per year.
EPS 1Y (TTM)0%
EPS 3Y3.11%
EPS 5Y65.96%
EPS Q2Q%-42.5%
Revenue 1Y (TTM)12.59%
Revenue growth 3Y25.89%
Revenue growth 5Y22.67%
Sales Q2Q%9.64%
3.2 Future
- Based on estimates for the next years, UTI will show a small growth in Earnings Per Share. The EPS will grow by 5.89% on average per year.
- UTI is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.84% yearly.
EPS Next Y-31.19%
EPS Next 2Y-10.6%
EPS Next 3Y5.89%
EPS Next 5YN/A
Revenue Next Year9.48%
Revenue Next 2Y8.9%
Revenue Next 3Y8.84%
Revenue Next 5YN/A
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. UTI Valuation Analysis
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 36.59, the valuation of UTI can be described as expensive.
- The rest of the industry has a similar Price/Earnings ratio as UTI.
- When comparing the Price/Earnings ratio of UTI to the average of the S&P500 Index (27.42), we can say UTI is valued slightly more expensively.
- UTI is valuated quite expensively with a Price/Forward Earnings ratio of 38.95.
- UTI's Price/Forward Earnings is on the same level as the industry average.
- UTI's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.24.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 36.59 | ||
| Fwd PE | 38.95 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of UTI is on the same level as its industry peers.
- UTI's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 120.99 | ||
| EV/EBITDA | 17.7 |
4.3 Compensation for Growth
- UTI has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.55
EPS Next 2Y-10.6%
EPS Next 3Y5.89%
5. UTI Dividend Analysis
5.1 Amount
- UTI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
UTI Fundamentals: All Metrics, Ratios and Statistics
35.49
-0.84 (-2.31%)
Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Services
GICS IndustryDiversified Consumer Services
Earnings (Last)02-04 2026-02-04/amc
Earnings (Next)05-06 2026-05-06
Inst Owners96.88%
Inst Owner Change0.96%
Ins Owners2.49%
Ins Owner Change3.2%
Market Cap1.95B
Revenue(TTM)855.03M
Net Income(TTM)53.69M
Analysts81.82
Price Target38.42 (8.26%)
Short Float %6.76%
Short Ratio4.54
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0.03
Dividend Growth(5Y)-34.43%
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)47.57%
Min EPS beat(2)28.91%
Max EPS beat(2)66.22%
EPS beat(4)4
Avg EPS beat(4)59.42%
Min EPS beat(4)28.91%
Max EPS beat(4)73.27%
EPS beat(8)7
Avg EPS beat(8)48.68%
EPS beat(12)11
Avg EPS beat(12)85.96%
EPS beat(16)14
Avg EPS beat(16)183.11%
Revenue beat(2)2
Avg Revenue beat(2)0.64%
Min Revenue beat(2)0.47%
Max Revenue beat(2)0.82%
Revenue beat(4)4
Avg Revenue beat(4)1.74%
Min Revenue beat(4)0.47%
Max Revenue beat(4)4.51%
Revenue beat(8)8
Avg Revenue beat(8)2.01%
Revenue beat(12)12
Avg Revenue beat(12)2.35%
Revenue beat(16)15
Avg Revenue beat(16)2.9%
PT rev (1m)0%
PT rev (3m)0.64%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-103.86%
EPS NY rev (1m)0%
EPS NY rev (3m)0.72%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.41%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 36.59 | ||
| Fwd PE | 38.95 | ||
| P/S | 2.28 | ||
| P/FCF | 120.99 | ||
| P/OCF | 25.21 | ||
| P/B | 5.81 | ||
| P/tB | 6.82 | ||
| EV/EBITDA | 17.7 |
EPS(TTM)0.97
EY2.73%
EPS(NY)0.91
Fwd EY2.57%
FCF(TTM)0.29
FCFY0.83%
OCF(TTM)1.41
OCFY3.97%
SpS15.54
BVpS6.11
TBVpS5.21
PEG (NY)N/A
PEG (5Y)0.55
Graham Number11.5432 (-67.47%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.44% | ||
| ROE | 15.98% | ||
| ROCE | 11.63% | ||
| ROIC | 8.69% | ||
| ROICexc | 11.82% | ||
| ROICexgc | 13.27% | ||
| OM | 8.38% | ||
| PM (TTM) | 6.28% | ||
| GM | 49.62% | ||
| FCFM | 1.89% |
ROA(3y)4.45%
ROA(5y)3.5%
ROE(3y)11.95%
ROE(5y)9.34%
ROIC(3y)7.27%
ROIC(5y)5.89%
ROICexc(3y)10.21%
ROICexc(5y)8.25%
ROICexgc(3y)11.54%
ROICexgc(5y)9.21%
ROCE(3y)9.72%
ROCE(5y)7.88%
ROICexgc growth 3Y34.26%
ROICexgc growth 5YN/A
ROICexc growth 3Y33.76%
ROICexc growth 5YN/A
OM growth 3Y17.03%
OM growth 5YN/A
PM growth 3Y35.13%
PM growth 5Y53.06%
GM growth 3Y-13.36%
GM growth 5Y-8.21%
F-Score7
Asset Turnover1.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | 6.28 | ||
| Debt/EBITDA | 0.93 | ||
| Cap/Depr | 181.06% | ||
| Cap/Sales | 7.17% | ||
| Interest Coverage | 13.88 | ||
| Cash Conversion | 73.39% | ||
| Profit Quality | 30.06% | ||
| Current Ratio | 1.14 | ||
| Quick Ratio | 1.14 | ||
| Altman-Z | 3.95 |
F-Score7
WACC8.73%
ROIC/WACC1
Cap/Depr(3y)145.01%
Cap/Depr(5y)268.95%
Cap/Sales(3y)5.89%
Cap/Sales(5y)11.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3Y3.11%
EPS 5Y65.96%
EPS Q2Q%-42.5%
EPS Next Y-31.19%
EPS Next 2Y-10.6%
EPS Next 3Y5.89%
EPS Next 5YN/A
Revenue 1Y (TTM)12.59%
Revenue growth 3Y25.89%
Revenue growth 5Y22.67%
Sales Q2Q%9.64%
Revenue Next Year9.48%
Revenue Next 2Y8.9%
Revenue Next 3Y8.84%
Revenue Next 5YN/A
EBIT growth 1Y-0.64%
EBIT growth 3Y47.33%
EBIT growth 5YN/A
EBIT Next Year46.18%
EBIT Next 3Y27.41%
EBIT Next 5YN/A
FCF growth 1Y371.76%
FCF growth 3YN/A
FCF growth 5Y99.08%
OCF growth 1Y35.47%
OCF growth 3Y28.35%
OCF growth 5Y54.57%
UNIVERSAL TECHNICAL INSTITUT / UTI Fundamental Analysis FAQ
What is the fundamental rating for UTI stock?
ChartMill assigns a fundamental rating of 5 / 10 to UTI.
What is the valuation status for UTI stock?
ChartMill assigns a valuation rating of 2 / 10 to UNIVERSAL TECHNICAL INSTITUT (UTI). This can be considered as Overvalued.
What is the profitability of UTI stock?
UNIVERSAL TECHNICAL INSTITUT (UTI) has a profitability rating of 7 / 10.
What is the valuation of UNIVERSAL TECHNICAL INSTITUT based on its PE and PB ratios?
The Price/Earnings (PE) ratio for UNIVERSAL TECHNICAL INSTITUT (UTI) is 36.59 and the Price/Book (PB) ratio is 5.81.
Can you provide the expected EPS growth for UTI stock?
The Earnings per Share (EPS) of UNIVERSAL TECHNICAL INSTITUT (UTI) is expected to decline by -31.19% in the next year.